ๆญฃๅœจๅŠ ่ฝฝ่ง†้ข‘...

่ง†้ข‘ๅŠ ่ฝฝๅคฑ่ดฅ

่ฟ”ๅ›ž้ฆ–้กต

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month. $ABVX Watch the full video:

BiotechTV's profile picture

BiotechTV

11,757 subscribers

22,305 ๆฌก่ง‚็œ‹ โ€ข 1 ไธชๆœˆๅ‰ โ€ขvia X (Twitter)

LIVE

Anya Rossiโ€ข Live Now

Private livecam show

0 ๆก่ฏ„่ฎบ

ๆš‚ๆ— ่ฏ„่ฎบ

ๅŽŸๅง‹ๅธ–ๅญ็š„่ฏ„่ฎบๅฐ†ๆ˜พ็คบๅœจ่ฟ™้‡Œ

็›ธๅ…ณ่ง†้ข‘

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year. $ABVX Full video:
3:51

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year. $ABVX Full video:

BiotechTV

73,893 ๆฌก่ง‚็œ‹ โ€ข 7 ไธชๆœˆๅ‰

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Solid Biosciences's CEO Bo Cumbo discusses today's data release of the company's microdystrophin gene therapy candidate for Duchenne muscular dystrophy. $SLDB Full video:
7:29

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Solid Biosciences's CEO Bo Cumbo discusses today's data release of the company's microdystrophin gene therapy candidate for Duchenne muscular dystrophy. $SLDB Full video:

BiotechTV

42,139 ๆฌก่ง‚็œ‹ โ€ข 1 ๅนดๅ‰

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: With three approved products and filings for more over the near term, Axsome Therapeutics's CEO describes the scale and reach this company is building in the CNS space. $AXSM Full video:
3:36

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: With three approved products and filings for more over the near term, Axsome Therapeutics's CEO describes the scale and reach this company is building in the CNS space. $AXSM Full video:

BiotechTV

20,894 ๆฌก่ง‚็œ‹ โ€ข 1 ๅนดๅ‰

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: After switching to a new GalNAc-LNP delivery vehicle a year ago, @VerveTx today announced the initial safety and efficacy data from its VERVE-102 PCSK9 based editor. Co-Founder & CEO Sek Kathiresan MD covers the data. $VERV Full video:
5:19

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: After switching to a new GalNAc-LNP delivery vehicle a year ago, @VerveTx today announced the initial safety and efficacy data from its VERVE-102 PCSK9 based editor. Co-Founder & CEO Sek Kathiresan MD covers the data. $VERV Full video:

BiotechTV

22,484 ๆฌก่ง‚็œ‹ โ€ข 1 ๅนดๅ‰

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib. $CRVS Full video:
4:58

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib. $CRVS Full video:

BiotechTV

24,695 ๆฌก่ง‚็œ‹ โ€ข 6 ไธชๆœˆๅ‰

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Prime Medicine's new CEO Allan Reine walks us through the prime editing company's new focused pipeline. $PRME Full video:
7:20

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Prime Medicine's new CEO Allan Reine walks us through the prime editing company's new focused pipeline. $PRME Full video:

BiotechTV

37,174 ๆฌก่ง‚็œ‹ โ€ข 1 ๅนดๅ‰

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Renowned scientist and entrepreneur Greg Verdine announced $263M in new funding for his company LifeMine Therapeutics. Participating investors include names like Bezos and Gates. See the full interview:
1:54

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Renowned scientist and entrepreneur Greg Verdine announced $263M in new funding for his company LifeMine Therapeutics. Participating investors include names like Bezos and Gates. See the full interview:

BiotechTV

20,218 ๆฌก่ง‚็œ‹ โ€ข 15 ๅคฉๅ‰

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies. CEO Jack O'Meara explains. Full video:
4:35

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies. CEO Jack O'Meara explains. Full video:

BiotechTV

19,198 ๆฌก่ง‚็œ‹ โ€ข 10 ไธชๆœˆๅ‰

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Roche will pay Manifold Bio $55M up front, and up to $2B in milestones, to collaborate on multiple next-generation brain shuttles for neurological diseases. Full video:
4:17

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Roche will pay Manifold Bio $55M up front, and up to $2B in milestones, to collaborate on multiple next-generation brain shuttles for neurological diseases. Full video:

BiotechTV

18,780 ๆฌก่ง‚็œ‹ โ€ข 9 ไธชๆœˆๅ‰

๐‰๐ž๐Ÿ๐Ÿ๐ž๐ซ๐ข๐ž๐ฌ ๐‹๐จ๐ง๐๐จ๐ง: Olema Oncology more than doubled yesterday when Roche announced surprise data for its oral SERD - the CEO reacts and shares the development program for Olema's competing asset. $OLEM Full video:
4:00

๐‰๐ž๐Ÿ๐Ÿ๐ž๐ซ๐ข๐ž๐ฌ ๐‹๐จ๐ง๐๐จ๐ง: Olema Oncology more than doubled yesterday when Roche announced surprise data for its oral SERD - the CEO reacts and shares the development program for Olema's competing asset. $OLEM Full video:

BiotechTV

12,936 ๆฌก่ง‚็œ‹ โ€ข 9 ไธชๆœˆๅ‰

๐€๐ˆ ๐๐ž๐ฐ๐ฌ: Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today. Full video:
3:11

๐€๐ˆ ๐๐ž๐ฐ๐ฌ: Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today. Full video:

BiotechTV

15,086 ๆฌก่ง‚็œ‹ โ€ข 8 ไธชๆœˆๅ‰

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: BridgeBio Pharma Founder & CEO Neil Kumar and Roivant Sciences CEO Matt Gline discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term. $BBIO $ROIV Watch the full episode:
6:11

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: BridgeBio Pharma Founder & CEO Neil Kumar and Roivant Sciences CEO Matt Gline discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term. $BBIO $ROIV Watch the full episode:

BiotechTV

11,639 ๆฌก่ง‚็œ‹ โ€ข 4 ไธชๆœˆๅ‰

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: Perceptive Advisors' Joe Edelman discusses with Roivant Sciences CEO Matt Gline how biotech investing has changed over his extensive career, and his philosophy on running an investment firm. Watch the full episode:
3:18

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: Perceptive Advisors' Joe Edelman discusses with Roivant Sciences CEO Matt Gline how biotech investing has changed over his extensive career, and his philosophy on running an investment firm. Watch the full episode:

BiotechTV

16,768 ๆฌก่ง‚็œ‹ โ€ข 1 ไธชๆœˆๅ‰

๐€๐’๐‡ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“: Corvus CEO Richard Miller believes that ITK inhibitors can have the same broad impact on T-cell diseases as BTK inhibitors have had on B-cell diseases - he would know. $CRVS Full video:
3:33

๐€๐’๐‡ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“: Corvus CEO Richard Miller believes that ITK inhibitors can have the same broad impact on T-cell diseases as BTK inhibitors have had on B-cell diseases - he would know. $CRVS Full video:

BiotechTV

17,673 ๆฌก่ง‚็œ‹ โ€ข 8 ไธชๆœˆๅ‰

๐€๐’๐‡ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ’: Legend Biotech CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more. #ASH24 $LEGN Full video:
0:48

๐€๐’๐‡ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ’: Legend Biotech CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more. #ASH24 $LEGN Full video:

BiotechTV

16,621 ๆฌก่ง‚็œ‹ โ€ข 1 ๅนดๅ‰

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Sana Bio's CEO Steve Harr describes the science behind the company's cell therapy program that aims to be a cure for type 1 diabetes. $SANA Full video:
4:40

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Sana Bio's CEO Steve Harr describes the science behind the company's cell therapy program that aims to be a cure for type 1 diabetes. $SANA Full video:

BiotechTV

19,210 ๆฌก่ง‚็œ‹ โ€ข 7 ไธชๆœˆๅ‰